Treatment and dosing of Helicobacter pylori infection: When pharmacology meets clinic

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 3, 2007, Pages 329-350

  Treiber, Gerhard ^a,c   Malfertheiner, Peter ^a   Klotz, Ulrich ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Antibiotic resistance; Dosing; Helicobacter pylori; Pharmacokinetics

Indexed keywords

ALCOHOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; BISMUTH CITRATE; BISMUTH DERIVATIVE; CIMETIDINE; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; KETOCONAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; ROXITHROMYCIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL DREAMING; AGGRESSION; AGITATION; ALLERGIC REACTION; ALLERGY; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANUS PRURITUS; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL VIRULENCE; BEHAVIOR CHANGE; BLOOD PRESSURE; BLURRED VISION; BRAIN DISEASE; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTATIC HEPATITIS; CHONDROPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEPERSONALIZATION; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; ENTEROCOLITIS; EOSINOPHILIA; ERADICATION THERAPY; ERYTHEMA; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FACE DISORDER; FECES; FLU LIKE SYNDROME; FLUSHING; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENOTYPE; GLOSSITIS; GYNECOMASTIA; HAIRY TONGUE; HALLUCINATION; HEARING LOSS; HEART ARRHYTHMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HOARSENESS; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; IMPOTENCE; INFLAMMATION; INSOMNIA; INTERSTITIAL NEPHRITIS; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LOOSE FECES; LUNG DISEASE; MACULOPAPULAR RASH; MALAISE; MANIA; MAXIMUM PLASMA CONCENTRATION; MEASLES LIKE RASH; MENTAL DISEASE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NEUTROPENIA; NIGHT SWEAT; NIGHTMARE; NONHUMAN; OPTIC NEURITIS; PANCREATITIS; PARESTHESIA; PEPTIC ULCER; PERICARDITIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PROCTITIS; PSYCHOSIS; REVIEW; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SKIN DISCOLORATION; SMELLING DISORDER; SOMNOLENCE; SORE THROAT; STEVENS JOHNSON SYNDROME; STOMACH CANCER; STOMACH CARCINOID; STOMACH GLAND POLYP; STOMATITIS; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; TENDON RUPTURE; THORAX PAIN; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THRUSH; THYROID GLAND; TINNITUS; TONGUE; TONGUE DISEASE; TOOTH DISCOLORATION; TREMOR; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINE; URTICARIA; VAGINITIS; VERTIGO; VESICULAR RASH; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 33847035081     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.3.329     Document Type: Review

References (117)

1. SUERBAUM S, MICHETTI P: Helicobacter pylori infection. N. Engl. J. Med. (2002) 347:1175-1186.
2. EL-OMAR EM, CARRINGTON M, CHOW WH et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 404:398-402.
3. EL-OMAR EM, CHOW WH, RABKIN CS: Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology (2001) 121(4):1002-1004.
4. EL-OMAR EM, OIEN K, MURRAY LS et al.: Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology (2000) 118:22-30.
5. EL-OMAR EM, RABKIN CS, GAMMON MD et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 124:1193-1201.
6. FURUTA T, EL-OMAR EM, XIAO F et al.: Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology (2002) 123:92-105.
7. PENSTON JG: Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol. Ther. (1996) 10:469-486.
8. TREIBER G, LAMBERT JR: The impact of Helicobacter pylori eradication on peptic ulcer healing. Am. J. Gastroenterol. (1998) 93(7):1080-1084.
9. FORD A, DELANEY B, FORMAN D, MOAYYEDI P: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst. Rev. (2004) 4:CD003840.
10. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection-the Maastricht III Consensus Report. Gut (2006) (In press).
11. PETERSON WL, FENDRICK AM, CAVE DR et al.: Helicobacter pylori-related disease: guidelines for testing and treatment. Arch. Intern. Med. (2000) 160:1285-1291.
12. UEMURA N, OKAMOTO S: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol. Clin. North Am. (2000) 29(4):819-827.
13. UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345:784-789.
14. WONG BC, LAM SK, WONG WM et al.: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA (2004) 291(2):187-194.
15. HUANG JQ, ZHENG GF, SUMANAC K, IRVINE EJ, HUNT RH: Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 125(6):1636-1644.
16. HUNT RH: Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Am. J. Med. (2004) 117(Suppl. 5A):86S-91S.
17. YAMAOKA Y, OJO O, FUJIMOTO S et al.: Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2006) 55(6):775-781
18. GRAHAM DY, SHIOTANI A: The time to eradicate gastric cancer is now. Gut (2005) 54:735-738.
19. AEBISCHER T, SCHMITT A, WALDUCK AK, MEYER TF: Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. (2005) 295(5):343-353.
20. DEL GIUDICE G, COVACCI A, TELFORD JL, MONTECUCCO C, RAPPUOLI R: The design of vaccines against Helicobacter pylori and their development. Ann. Rev. Immunol. (2001) 19:523-563.
21. ERNST PB, PEURA DA, CROWE SE: The translation of Helicobacter pylori basic research to patient care. Gastroenterology (2006) 130(1):188-206; quiz 212-3.
22. LOUGHLIN MF: Novel therapeutic targets in Helicobacter pylori. Expert. Opin. Ther. Targets (2003) 7:725-735.
23. MALFERTHEINER P, PEITZ U, TREIBER G:What constitutes failure for Helicobacter pylori eradication therapy? Can. J. Gastroenterol. (2003) 17 (Suppl. B):53B-57B.
24. CONWAY BR: Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr. Pharm. Des. (2005) 11:775-790.
25. SACHS G: Proton pump inhibitors and acid-related diseases. Pharmacotherapy (1997) 17:22-37.
26. KLOTZ U: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. (2000) 38:243-270.
27. FURUTA T, SHIRAI N, SUGIMOTO M, OHASHI K, ISHIZAKI T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics (2004) 5(2):181-202.
28. KLOTZ U, SCHWAB M, TREIBER G: CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. (2004) 95(1):2-8.
29. PADOL S, YUAN Y, THABANE M, PADOL IT, HUNT RH: The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. (2006) 101:1467-1475
30. SCHWAB M, KLOTZ U, HOFMANN UG et al.: Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin. Pharmacol. Ther. (2005) 78(6):627-634.
31. PETERSON WL: The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther. (1997) 11 (Suppl. 1):21-25.
32. MIDOLO PD, TURNIDGE JD, LAMBERT JR: Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J. Antimicrob. Chemother. (1997) 39:331-337.
33. SCHREIBER S, BUCKER R, GROLL C et al.: Rapid loss of motility of Helicobacter pylori in the gastric lumen in vivo. Infect. Immun. (2005) 73:1584-1589.
34. SCHREIBER S, KONRADT M, GROLL C et al.: The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl. Acad. Sci. USA (2004) 101:5024-5029.
35. GODDARD AF, JESSA MJ, BARRETT DA, SHAW PN et al.: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology (1996) 111(2):358-367.
36. GODDARD AF, SPILLER RC: The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol. Ther. (1996) 10:105-109.
37. GODDARD AF, SPILLER RC: In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents. Antimicrob. Agents Chemother. (1997) 41:1246-1249.
38. SHERWOOD PV, WIBAWA JI, ATHERTON JC et al.: Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut (2002) 51:490-495.
39. ERAH PO, GODDARD AF, BARRETT DA, SHAW PN, SPILLER RC: The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. (1997) 39:5-12.
40. GUSTAVSON LE, KAISER JF, EDMONDS AL et al.: Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. (1995) 39(9):2078-2083.
41. TREIBER G, GLADZIWA U, ITTEL TH et al.: Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol. Ther. (1991) 5:491-502.
42. TREIBER G, WALKER S, KLOTZ U: Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin. Pharmacol. Ther. (1994) 55(5):486-491.
43. PHILLIPS RH, WHITEHEAD MW, DOIG LA et al.: Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter (2001) 6(2):151-156.
44. TILLMAN LA, DRAKE FM, DIXON JS, WOOD JR: Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol. Ther. (1996) 10(4):459-467.
45. TREIBER G: The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am. J. Gastroenterol. (1996) 91(2):246-257.
46. AMMON S, TREIBER G, KEES F, KLOTZ U: Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2000) 14:759-766.
47. DORE MP, KWON DH, SEPULVEDA AR, GRAHAM DY, REALDI G: Stable amoxicillin resistance in Helicobacter pylori. Helicobacter (2001) 6(1):79.
48. NAKAMURA M, SPILLER RC, BARRETT DA et al.: Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter (2003) 8(4):294-299.
49. TREIBER G, AMMON S, KLOTZ U: Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol. Ther. (1997) 11(4):711-718.
50. COOREMAN MP, KRAUSGRILL P, HENGELS KJ: Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob. Agents Chemother. (1993) 37:1506-1509.
51. HULTEN K, RIGO R, GUSTAFSSON I, ENGSTRAND L: New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob. Agents Chemother. (1996) 40:2727-2731.
52. MAINZ D, BORNER K, KOEPPE P, KOTWAS J, LODE H: Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J. Antimicrob. Chemother. (2002) 50(5):699-706.
53. ORTIZ RA, CALAFATTI SA, CORAZZI A et al.: Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole. Aliment Pharmacol. Ther. (2002) 16(6):1163-1170.
54. POMMERIEN W, BRAUN M, IDSTROM JP, WRANGSTADH M, LONDONG W: Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Aliment Pharmacol. Ther. (1996) 10(3):295-301.
55. LAINE L, FENNERTY MB, OSATO M et al.: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. (2000) 95(12):3393-3398.
56. TREIBER G, WITTIG J, AMMON S, WALKER S, VAN DOORN LJ, KLOTZ U: Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch. Intern. Med. (2002) 162(2):153-160.
57. MEGRAUD F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol. Ther. (1997) 11(Suppl. 1):43-53.
58. MEGRAUD F, ROBERTS P, WILLIAMSON R: Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter (2000) 5:222-226.
59. CALABRESI L, PAZZUCCONI F, FERRARA S, DI PAOLO A, TACCA MD, SIRTORI C: Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol. Res. (2004) 49:493-499.
60. MARKHAM A, MCTAVISH D: Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs (1996) 51:161-178.
61. MEGRAUD F: Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist Updat. (2001) 4:178-186.
62. KWON DH, HULTEN K, KATO M et al.: DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob. Agents Chemother. (2001) 45:2609-2615.
63. MANES G, BALZANO A: Tinidazole: from protozoa to Helicobacter pylori-the past, present and future of a nitroimidazole with peculiarities. Expert Rev. Anti. Infect. Ther. (2004) 2:695-705.
64. SPENARD J, AUMAIS C, MASSICOTTE J et al.: Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication. Br. J. Clin. Pharmacol. (2005) 60:374-377.
65. VAN ZANTEN SJ, GOLDIE J, HOLLINGSWORTH J et al.: Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J. Clin. Pathol. (1992) 45:225-227.
66. XIA HH, YU WONG BC, TALLEY NJ, LAM SK: Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin. Pharmacother. (2002) 3:1301-1311.
67. BROGDEN RN, FITTON A: Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 47(6):983-1009.
68. VON ROSENSTEIL NA, ADAM D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. (1995) 13(2):105-122.
69. BOCK H, KOOP H, LEHN N, HEEP M: Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J. Clin. Gastroenterol. (2000) 31:222-225.
70. GISBERT JP, GISBERT JL, MARCOS S, OLIVARES D, PAJARES JM: Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol. Ther. (2005) 22:1041-1046.
71. GISBERT JP, GISBERT JL, MARCOS S, PAJARES JM: Empirical Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Dig. Liver Dis. (2004) 36:7-12.
72. GISBERT JP, PAJARES JM: Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol. Ther. (2002) 16:1047-1057.
73. GISBERT JP, PAJARES JM: Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Helicobacter (2005) 10:363-372.
74. MEGRAUD F: Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr. Infect. Dis. Rep. (2005) 7:115-120.
75. PERRI F, FESTA V, CLEMENTE R et al.: Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. (2001) 96:58-62.
76. QASIM A, SEBASTIAN S, THORNTON O et al.: Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol. Ther. (2005) 21:91-96.
77. WONG WM, GU Q, LAM SK et al.: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol. Ther. (2003) 17:553-560.
78. CALAFATTI SA, ORTIZ RA, DEGUER M, MARTINEZ M, PEDRAZZOLI JJ: Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 52(2):205-209.
79. ISAKOV V, DOMAREVA I, KOUDRYAVTSEVA L, MAEV I, GANSKAYA Z: Furazolidone-based triple 'rescue therapy' versus quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol. Ther. (2002) 16:1277-1282.
80. MALEKZADEH R, ANSARI R, VAHEDI H et al.: Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol. Ther. (2000) 14:299-303.
81. MEGRAUD F: Basis for the management of drug-resistant Helicobacter pylori infection. Drugs (2004) 64(17):1893-1904.
82. TREIBER G, AMMON S, MALFERTHEINER P, KLOTZ U: Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter (2002) 7(4):225-231.
83. ALTAMIRANO A, BONDANI A: Adverse reactions to furazolidone and other drugs. A comparative review. Scand J. Gastroenterol. Suppl. (1989) 169:70-80.
84. GISBERT JP, MORENA F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol. Ther. (2006) 23:35-44.
85. CROOM KF, GOA KL: Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs (2003) 63(24):2769-2802.
86. OSATO MS, REDDY R, REDDY SG, PENLAND RL, MALATY HM, GRAHAM DY: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. (2001) 161:1217-1220.
87. WU JY, KIM JJ, REDDY R, WANG WM, GRAHAM DY, KWON DH: Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob. Agents Chemother. (2005) 49:578-583.
88. DE BOER WA, BORODY TJ: Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig. Liver Dis. (2000) 32(8):673-675.
89. DORE MP, LEANDRO G, REALDI G, SEPULVEDA AR, GRAHAM DY: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. (2000) 45(1):68-76.
90. DUCK WM, SOBEL J, PRUCKLER JM et al.: Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis. (2004) 10(6):1088-1094.
91. FISCHBACH LA, VAN ZANTEN S, DICKASON J: Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol. Ther. (2004) 20(10):1071-1082.
92. GLOCKER E, KIST M: Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J. Clin. Microbiol. (2004) 42:2241-2246.
93. GRAHAM DY: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 115:1272-1277.
94. HOFFMAN PS: Antibiotic resistance mechanisms of Helicobacter pylori. Can. J. Gastroenterol. (1999) 13:243-249.
95. HOUBEN MH, VAN DE BEEK D, HENSEN EF, CRAEN AJ, RAUWS EA, TYTGAT GN: A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol. Ther. (1999) 13:1047-1055.
96. HUANG JQ, HUNT RH: Treatment after failure: the problem of 'non-responders'. Gut (1999) 45 (Suppl. 1):I40-I44.
97. HUNT RH, SMAILL FM, FALLONE CA et al.: Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group. Can. J. Gastroenterol. (2000) 14(10):862-868.
98. MEGRAUD F: H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 53(9):1374-1384.
99. WOLLE K, LEODOLTER A, MALFERTHEINER P, KONIG W: Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J. Med. Microbiol. (2002) 51:705-709.
100. CALVET X, GARCIA N, LOPEZ T et al.: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol. Ther. (2000) 14(5):603-609.
101. GENE E, CALVET X, AZAGRA R, GISBERT JP: Triple versus quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol. Ther. (2003) 17(9):1137-1143.
102. GISBERT JP, GONZALEZ L, CALVET X: Systematic review and meta-analysis: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter (2005) 10:157-171.
103. GISBERT JP, PAJARES JM: Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol. Ther. (2005) 21:795-804.
104. GISBERT JP, GONZALEZ L, CALVET X et al.: Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2000) 14(10):1319-1328.
105. GRAHAM DY, HAMMOUD F, EL-ZIMAITY HM et al.: Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol. Ther. (2003) 17(10):1229-1236.
106. HUANG J, HUNT RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol. Ther. (1999) 13(6):719-729.
107. JANSSEN MJ, LAHEIJ RJ, DE BOER WA, JANSEN JB: Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol. Ther. (2005) 21:341-345.
108. LAHEIJ RJ, ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Helicobacter pylori infection- a meta-analysis. Aliment Pharmacol. Ther. (1999) 13:857-864.
109. MOAYYEDI P, SOO S, DEEKS J, DELANEY B et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. (2005) 1:CD002096.
110. PIPKIN GA, WILLIAMSON R, WOOD JR: Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (1998) 12:823-837.
111. KATELARIS PH, FORBES GM, TALLEY NJ, CROTTY B: A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 123(6):1763-1769.
112. DE BOER WA: Eradication therapy should be different for dyspeptic patients than for ulcer patients. Can. J. Gastroenterol. (2003) 17 (Suppl. B):41B-45B.
113. HUANG JQ, ZHENG GF, HUNT RH et al.: Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J. Gastroenterol. (2005) 11:2726-2732.
114. SUZUKI T, MATSUO K, SAWAKI A et al.: Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol. Ther. (2006) 24:273-80
115. TREIBER G, MALFERTHEINER P: CagA status and successful eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2006) 24:1261-1263
116. GRAHAM DY: Therapy of Helicobacter pylori: current status and issues. Gastroenterology (2000) 118(2 Suppl. 1):S2-S8.
117. TREIBER G: Treating H. pylori shorter than one week-a real future perspective? Z. Gastroenterol. (2000) 38(9):807-812.